Loading...
Please wait, while we are loading the content...
Similar Documents
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
| Content Provider | Scilit |
|---|---|
| Author | Sauter, Craig S. Matasar, Matthew J. Schöder, Heiko Devlin, Sean M. Drullinsky, Pamela Gerecitano, John Kumar, Anita Noy, Ariela Palomba, Maria L. Portlock, Carol S. Straus, David J. Zelenetz, Andrew D. McCall, Susan J. Miller, Shoshana T. Courtien, Amanda I. Younes, Anas Moskowitz, Craig H. |
| Copyright Year | 2018 |
| Description | Key Points Ibrutinib plus R-ICE was safe, tolerable, and was not prohibitive to mobilizing hematopoietic stem cells for autologous transplantation. A favorable early signal in all evaluable rel/ref non-GC DLBCL achieving a complete metabolic remission was observed. |
| Related Links | https://ashpublications.org/blood/article-pdf/131/16/1805/1467736/blood802561.pdf |
| Ending Page | 1808 |
| Page Count | 4 |
| Starting Page | 1805 |
| DOI | 10.1182/blood-2017-08-802561 |
| Journal | Blood |
| Issue Number | 16 |
| Volume Number | 131 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2018-04-19 |
| Access Restriction | Open |
| Subject Keyword | Hematology Research and Experimental Medicine Chemosensitive Diffuse Large B Cell Lymphoma Dlbcl Ibrutinib Phase I Study Phenotype Rel/ref Salvage Stem Cell Journal: Blood (Vol- 127, Issue- 16) |
| Content Type | Text |
| Resource Type | Article |